Neurocrine Raises INGREZZA Outlook as Core Products Grow

Transcript intelligence

What changed

Compared with Q2, management reported another record quarter, described double-digit growth across its three core products and raised full-year INGREZZA guidance. VYKAT XR has moved beyond its early launch phase, making the durability of new-patient additions and persistency more important to monitor.

Guidance delta

Management raised full-year INGREZZA revenue guidance to $2.9 billion, from the prior quarter's $2.825–$2.875 billion range.

Key takeaways

• Management attributed record Q3 product sales growth to all three core medicines: INGREZZA, CRENESITY and VYKAT XR.
• INGREZZA's higher full-year outlook reflects continued volume and new-prescription growth, while management also expects net-price concessions.
• CRENESITY's reported patient reach, persistency and adult uptake indicate continued commercial expansion, according to management.
• The pipeline includes planned 2027 Phase III readouts and earlier-stage obesity and gene-therapy programs; these are potential future drivers, not established outcomes.

Management priorities

• Sustain new prescriptions and volume growth for INGREZZA while managing pricing concessions.
• Expand CRENESITY uptake and continue commercial execution for VYKAT XR.
• Advance planned clinical programs, including 2027 Phase III readouts, and develop earlier-stage obesity and gene-therapy candidates.
• Continue salesforce expansion and prepare for the planned R&D Day.